Scarica l'app Stockscreener
25.43
0.51%
0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707 - geneonline.com
Transcript : Pfizer Inc.Special Call - MarketScreener
Is Pfizer Stock a Buy for Its Massive 7% Dividend Yield? A Trader’s Look - Daily Chhattisgarh News
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others - Fierce Pharma
Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC
Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE) - MSN
Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - Yahoo Finance
Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT - Insider Monkey
Pfizer (PFE) Stock: Analyst Targets Suggest 15% Upside as Company Touts Strong Margins and Dividend - Daily Chhattisgarh News
FDA Denies Pfizer's (PFE) Label Expansion for Talzenna in Prosta - GuruFocus
Pfizer bid to expand Talzenna label faces FDA snub (PFE:NYSE) - Seeking Alpha
Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China - geneonline.com
Pfizer (PFE) Option Activity Shows Mixed Sentiment | PFE Stock N - GuruFocus
Pfizer’s SWOT analysis: stock outlook amid pipeline progress, cost cuts - Investing.com
Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer - MarketScreener
Young minds dive into discovery at Pfizer School of Science Mobile Experience - Yahoo
Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer
BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com
Pfizer (PFE) Stock Shows Strong Rebound with Over 8% Monthly Gain, Halting Longer-Term Slide - Daily Chhattisgarh News
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp - The Globe and Mail
PFIZER INC : UBS remains Neutral - MarketScreener
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ... - Bluefield Daily Telegraph
Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC
4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts - 24/7 Wall St.
Pfizer (PFE) Sees Mixed Options Sentiment Amidst Modest Share In - GuruFocus
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents - marketscreener.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Scraps Bid for Depo-Provera Mass Tort Following Dismissal of Most Phila. Plaintiffs - Law.com
Cantor Fitzgerald Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer says drugmakers met with Trump admin to discuss lowering drug prices - Yahoo Finance
Request for Proposals: Pfizer Independent Research Grant Program 2025 - fundsforNGOs
10 Best Wide Moat Stocks To Buy Now - Insider Monkey
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Globe and Mail
Why China Biotech Is Getting a DeepSeek Moment, Too - Bloomberg.com
Pfizer Settles With Final Defendant in Mektovi Patent Lawsuit - Bloomberg Law News
Pfizer Stock Rallies Over 8% in a Month, but Faces Long-Term Headwinds - Daily Chhattisgarh News
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks - 24/7 Wall St.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - marketscreener.com
Cantor Fitzgerald holds Pfizer stock at Neutral with $24 target By Investing.com - Investing.com India
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE) - Seeking Alpha
No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says - Reuters
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves By Stocktwits - Investing.com India
Pfizer Stock Down Almost 11% YTD: Should You Buy The Dip? - Barchart.com
Pfizer (PFE) Sees Surge in Bullish Options Activity Ahead of Ear - GuruFocus
Pfizer CEO Says No Deals Yet in US Drug Price Talks - marketscreener.com
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip? - Yahoo Finance
Transcript : Pfizer Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
Pfizer at Goldman Sachs Conference: Strategic Insights on Drug Pricing and Growth - Investing.com
Is Pfizer Stock Underperforming The S&P 500? - Barchart.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
0.70%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):